Delivery Order SPE2DB25D3201-SPE2DB25FNWCC
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,776.31 by the Defense Logistics Agency for XELJANZ XR 11 MG tablets (30-count units) under a firm fixed-price contract type. The award was made on August 28, 2025, with an ultimate completion date of August 29, 2025, and represents a non-set-aside, competitively awarded procurement. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and primary distribution...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 4, 2025, for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This is a firm fixed price, non-set-aside contract with a ceiling value of approximately $55.1K and an ultimate completion date of September 5, 2025. The place of performance is the vendor's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency for XELJANZ XR 11 mg tablets in 30-count unit doses, valued at $18,565.52 under a firm fixed price contract type. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, carries no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $17,873.07 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on August 8, 2025, for XELJANZ XR 11 mg tablets (30-count packages). The award, which carries an ultimate completion date of August 11, 2025, represents a non-set-aside competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $69,353.78 on September 9, 2025, for the supply of XELJANZ XR 11 mg tablets (30-count units) by the Defense Logistics Agency. This non-set-aside, competitively awarded contract carries a firm fixed price structure and is scheduled for completion by September 10, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $5,437.40 by the Defense Logistics Agency's Medical Supply Chain on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price, non-set-aside contract calls for the delivery of XELJANZ XR 11 mg tablets in quantities of 30 units. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 12, 2025, for $17,709.48 under a firm fixed price contract type. The award covers the supply of Xeljanz XR 11 mg tablets in quantities of 30 units, a prescription medication used to treat inflammatory conditions. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $25,562.44 delivery order on September 12, 2025, for XELJANZ XR 11 mg tablets (30-count units) with a completion date of September 15, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $5,806.62 by the Defense Logistics Agency (DLA) for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units per package. This is a firm fixed-price, competitively awarded contract with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal procurement requirements through open competition. The contract was awarded on May 28, 2025, with an ultimate completion date of May 29, 2025, and...
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB25FNWCCDelivery Order
AmerisourceBergen Drug Corp received a delivery order award from the Defense Logistics Agency (DLA) on September 3, 2025, for XELJANZ XR 11 mg tablets in 30-count units, with a ceiling value of $10,286.16. This firm fixed price, non-set-aside contract is scheduled for completion by September 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This award reflects the contractor's ongoing role as a primary pharmaceutical supplier to the Defense Health Agency and other federal healthcare entities. The company's federal contract portfolio demonstrates extensive capabilities in delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains through competitively awarded delivery orders with firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 9/3/25 |